No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
COYA Coya Therapeutics
- 7.450
- +0.450+6.43%
Close Jul 22 16:00 ET
113.40MMarket Cap-8662P/E (TTM)
7.450High7.000Low16.70KVolume7.010Open7.000Pre Close119.33KTurnover0.14%Turnover RatioLossP/E (Static)15.22MShares10.69052wk High3.50P/B86.88MFloat Cap3.21052wk Low--Dividend TTM11.66MShs Float10.690Historical High--Div YieldTTM6.43%Amplitude3.210Historical Low7.144Avg Price1Lot Size
Full Hours
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Coya Shares Rise After Next Step to New Study of ALS Treatment
By Connor Hart Shares of Coya Therapeutics rose after the company said it is looking into a new study to further test a proprietary treatment of amyotrophic lateral sclerosis, also known as Lou
Express News | Coya Therapeutics : Got Notification From FDA Stating That Additional Non-Clinical Data Is Required Prior to Initiation of Coya 302 ALS Study
Express News | Coya Therapeutics Expands Sponsored Research Collaboration With Houston Methodist Research Institute Along With Funding From the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform Into the Clinic
Express News | Coya Therapeutics Inc Files for Shelf of up to 603,136 Shares of Common Stock by Selling Stockholder - SEC Filing
Express News | Rodman & Renshaw Initiates Coverage On Coya Therapeutics With Buy Rating, Announces Price Target of $18
Rodman & Renshaw Maintains Coya Therapeutics(COYA.US) With Buy Rating, Maintains Target Price $18
Rodman & Renshaw analyst Elemer Piros maintains $Coya Therapeutics(COYA.US)$ with a buy rating, and maintains the target price at $18.According to TipRanks data, the analyst has a success rate of 37.3
Comments
$Coya Therapeutics(COYA.US$ Reuters· just
Coya Therapeutics : Got Notification From FDA Stating That Additional Non-Clinical Data Is Required Prior to Initiation of Coya 302 ALS Study
Coya Therapeutics : Got Notification From FDA Stating That Additional Non-Clinical Data Is Required Prior to Initiation of Coya 302 ALS Study
$Coya Therapeutics(COYA.US$ Coya Therapeutics Expands Sponsored Research Collaboration With Houston Methodist Research Institute Along With Funding From the Johnson Center for Cellular Therapeutics to Advance Regulatory T Cell Exosome Platform Into the Clinic
$Coya Therapeutics(COYA.US$ Coya Therapeutics Announces Publication Of Phase 1 Study On CTLA4-Ig And Interleukin-2 Combination Therapy For ALS In Frontiers In Neurology
Benzinga· 2 mins ago
Data demonstrates halting of disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) at 24 weeks (6 months) and a consistent reduction in inflammation, oxidative stress, and enhanced Regulatory T cell (Treg) number and suppressive function in patients who were administered a combinatio...
Benzinga· 2 mins ago
Data demonstrates halting of disease progression in patients with Amyotrophic Lateral Sclerosis (ALS) at 24 weeks (6 months) and a consistent reduction in inflammation, oxidative stress, and enhanced Regulatory T cell (Treg) number and suppressive function in patients who were administered a combinatio...
$Coya Therapeutics(COYA.US$
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
Coya Therapeutics (NASDAQ: COYA) announced the acceptance of a peer-reviewed manuscript in Frontiers in Neurology. The study, titled 'A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,' highlights the halting of ALS p...
Coya Therapeutics Announces Acceptance of Peer-Reviewed Manuscript in the Medical Journal: Frontiers in Neurology
Coya Therapeutics (NASDAQ: COYA) announced the acceptance of a peer-reviewed manuscript in Frontiers in Neurology. The study, titled 'A Phase 1 Proof-of-Concept Study Evaluating Safety, Tolerability, and Biological Marker Responses with Combination Therapy of CTLA4-Ig and Interleukin-2 in Amyotrophic Lateral Sclerosis,' highlights the halting of ALS p...
$Coya Therapeutics(COYA.US$
NEWS
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
Positive
Completion of Phase 2 study on schedule.
Study funded by the Gates Foundation and Alzheimer’s Association, indicating strong support.
Topline results expected by summer 2024.
Preliminary data showed significant improvements in cognitive function.
Significant enhancement in regulatory T cell (Treg) function and...
NEWS
Coya Therapeutics Announces the Completion of a Controlled Phase 2 Study of Low Dose Interleukin-2 (LD IL-2) in Patients with Alzheimer’s Disease
Positive
Completion of Phase 2 study on schedule.
Study funded by the Gates Foundation and Alzheimer’s Association, indicating strong support.
Topline results expected by summer 2024.
Preliminary data showed significant improvements in cognitive function.
Significant enhancement in regulatory T cell (Treg) function and...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg